May 20, 2022
Bulletin interne de l'Institut Pasteur
SARS-CoV 2: A booster with a 'Lenti-COVID' vaccine candidate induces protective immunity in the respiratory mucosa in a preclinical model
Scientist at the Institut Pasteur- TheraVectys Joint Laboratory have demonstrated the efficacy of their lentiviral candidate vaccine “Lenti-COVID”, administered as an intranasal booster dose six months after primary vaccination with a messenger RNA vaccine, in a pre-clinical model. This intranasal booster induces protective immunity in the respiratory mucosa. These results pave the way for innovative vaccine strategy to reduce the viral transmission chain. The study is published in the journal Molecular Therapy.